Staar Surgical Co (Staar Surgical Co) ROCE % : 9.93% (As of Dec. 2023)

View and export this data going back to 1983. Start your Free Trial

What is Staar Surgical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Staar Surgical Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 9.93%.

Staar Surgical Co ROCE % Historical Data

The historical data trend for Staar Surgical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Staar Surgical Co ROCE % Chart

Staar Surgical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

7.58

3.48

12.99

13.19

7.11

Staar Surgical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															1.08	3.03	9.07	6.29	9.93

Staar Surgical Co ROCE % Calculation

Staar Surgical Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	28.097	/	( ( (418.818 - 51.716)	+	(488.692 - 65.036) )	/ 2 )
	=	28.097	/	( (367.102	+	423.656)	/ 2 )
	=	28.097	/	395.379
	=	7.11 %

Staar Surgical Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	41.62	/	( ( (471.521 - 56.775)	+	(488.692 - 65.036) )	/ 2 )
	=	41.62	/	( ( 414.746	+	423.656 )	/ 2 )
	=	41.62	/	419.201
	=	9.93 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Staar Surgical Co (NAS:STAA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Staar Surgical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Staar Surgical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Staar Surgical Co (Staar Surgical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Staar Surgical Co (NAS:STAA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SR3:Germany SR3:Germany

Address

25651 Atlantic Ocean Drive, Lake Forest, CA, USA, 92630

Website

https://www.staar.com

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also make lenses which are used in surgery that treats cataracts. The company offers products are ICLs used in refractive surgery and IOLs used in cataract surgery. The company generated sales are from the ophthalmic surgical product segment.

Executives

Broadwood Partners Lp	10 percent owner	BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Elizabeth Yeu Lin	director	25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
Aimee S Weisner	director	ONE EDWARDS WAY, IRVINE CA 92614
Warren Foust	officer: Chief Operating Officer	17 MAGNOLIA DRIVE, LADERA RANCH CA 92694
Magda Michna	officer: Chief Clinical, Regulatory,	C/O PRESBIA, 8845 IRVINE CENTER DRIVE, SUITE 100, IRVINE CA 92618
Keith Holliday	officer: V.P., Research & Development	1911 WALKER AVENUE, MONROVIA CA 91016
Robert Studholme	officer: Senior VP, Operations	25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
James E Francese	officer: VP, Global Marketing	1911 WALKER AVE, MONROVIA CA 91016
Caren L Mason	director	2523 PARK RIDGE DRIVE, ESCONDIDO CA 92025
Samuel J Gesten	officer: VP, General Counsel	1911 WALKER AVENUE, MONROVIA CA 91016
Patrick F. Williams	officer: Chief Financial Officer	C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Hans-martin Blickensdoerfer	officer: VP, International Marketing	1911 WALKER AVENUE, MONROVIA CA 91016
Lou Silverman	director
Graydon C. Hansen	officer: Sr. VP, Global Operations	25651 ATLANTIC OCEAN DRIVE, LAKE FORST CA 92630
Jon K. Hayashida	officer: VP, Global Clinical, Medical	25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630